BR112015001989A8 - uso de butilidenoftalida (bp) - Google Patents

uso de butilidenoftalida (bp) Download PDF

Info

Publication number
BR112015001989A8
BR112015001989A8 BR112015001989A BR112015001989A BR112015001989A8 BR 112015001989 A8 BR112015001989 A8 BR 112015001989A8 BR 112015001989 A BR112015001989 A BR 112015001989A BR 112015001989 A BR112015001989 A BR 112015001989A BR 112015001989 A8 BR112015001989 A8 BR 112015001989A8
Authority
BR
Brazil
Prior art keywords
compound
group
optionally
alkyl
pharmaceutically acceptable
Prior art date
Application number
BR112015001989A
Other languages
English (en)
Other versions
BR112015001989A2 (pt
BR112015001989B1 (pt
Inventor
Harn Horng-Jyh
Hsueh Kuo-Wei
Lin Shinn-Zong
Chiou Tzyy-Wen
Original Assignee
Univ China Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ China Medical filed Critical Univ China Medical
Publication of BR112015001989A2 publication Critical patent/BR112015001989A2/pt
Publication of BR112015001989A8 publication Critical patent/BR112015001989A8/pt
Publication of BR112015001989B1 publication Critical patent/BR112015001989B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1/1 resumo composição farmacêutica para inibir a autofagia de neurônios motores e uso da mesma uma composição farmacêutica para inibir a autofagia de neurônios motores, compreendendo uma quantidade eficaz de um ingrediente ativo selecionado a partir do grupo que consiste de um composto de fórmula (i), um sal farmaceuticamente aceitável do composto, um éster farmaceuticamente aceitável do composto e as combinações dos mesmos: (i), em que, a é um grupo alquila c1-c5, opcionalmente, tendo uma ou mais ligações insaturadas, e sendo opcionalmente substituído por um ou mais substituintes selecionados a partir do grupo que consiste em -oh, = o, e alquila c1-c3; x é h, oh, , ou ; y é o ou s e pode, opcionalmente, se ligar com a para formar um anel de cinco membros; e r1 é h ou um grupo alquila c1-c20 substituído ou não substituído, em que um ou mais -ch2de alquila c1-c20 s ão opcionalmente substituídos por nh-ou -o- .
BR112015001989-7A 2012-08-17 2012-08-17 Uso de butilidenoftalida (bp) BR112015001989B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/080291 WO2014026372A1 (zh) 2012-08-17 2012-08-17 用于抑制运动神经元自体吞噬的医药组合物及其应用

Publications (3)

Publication Number Publication Date
BR112015001989A2 BR112015001989A2 (pt) 2017-07-04
BR112015001989A8 true BR112015001989A8 (pt) 2018-03-06
BR112015001989B1 BR112015001989B1 (pt) 2022-06-14

Family

ID=50101210

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001989-7A BR112015001989B1 (pt) 2012-08-17 2012-08-17 Uso de butilidenoftalida (bp)

Country Status (9)

Country Link
EP (1) EP2992879B1 (pt)
JP (1) JP6178802B2 (pt)
KR (1) KR101695801B1 (pt)
AU (1) AU2012387970B2 (pt)
BR (1) BR112015001989B1 (pt)
ES (1) ES2655834T3 (pt)
PH (1) PH12015500047B1 (pt)
RU (1) RU2585372C1 (pt)
WO (1) WO2014026372A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI511727B (zh) 2014-07-02 2015-12-11 Everfront Biotech Inc 苯酞化合物之應用
NZ728386A (en) * 2014-07-04 2018-02-23 Everfront Biotech Inc Use of phthalide compound
FR3055548B1 (fr) 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
WO2019118734A1 (en) 2017-12-13 2019-06-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating motor neuron diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05247022A (ja) * 1990-07-10 1993-09-24 Tsumura & Co 新規フタリドおよびフタリドを有効成分とする脳機能改善剤
WO2002060234A2 (en) * 2000-11-22 2002-08-08 Yong Chao Xia Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
JP2008542226A (ja) * 2005-05-24 2008-11-27 ディーエスエム アイピー アセッツ ビー．ブイ． 炎症性障害の治療のためのリグスチリド誘導体
WO2008017491A1 (en) * 2006-08-11 2008-02-14 Dsm Ip Assets B.V. Ligustilide derivatives for the treatment of disorders of the central nervous system
TWI331033B (en) * 2007-04-26 2010-10-01 Yangsen Biotechnology Co Ltd Composition for inhibiting no and/or prostaglandin e2 synthesis and uses thereof

Also Published As

Publication number Publication date
BR112015001989A2 (pt) 2017-07-04
AU2012387970B2 (en) 2015-10-29
WO2014026372A1 (zh) 2014-02-20
RU2585372C1 (ru) 2016-05-27
EP2992879A1 (en) 2016-03-09
NZ703195A (en) 2016-06-24
AU2012387970A1 (en) 2015-01-22
PH12015500047A1 (en) 2015-03-02
KR101695801B1 (ko) 2017-01-13
JP2015506963A (ja) 2015-03-05
EP2992879A4 (en) 2016-05-11
JP6178802B2 (ja) 2017-08-09
KR20150043288A (ko) 2015-04-22
ES2655834T3 (es) 2018-02-21
PH12015500047B1 (en) 2015-03-02
BR112015001989B1 (pt) 2022-06-14
EP2992879B1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CA2875877C (en) Syk inhibitors
EP4252848A3 (en) Oxysterols and methods of use thereof
EP4316591A3 (en) Oxysterols and methods of use thereof
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
BR112012024017A2 (pt) compostos derivados de triazina dissubstituída farmaceuticamemnte ativios, composição farmacêutica, método para a síntese destes e uso dos mesmos
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
DOP2014000121A (es) Derivados de betulina
CY1115043T1 (el) Φαρμακευτικο σκευασμα
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
CO6630184A2 (es) Formulaciones famacéuticas que comprenden derivados de 1 (beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de sglt
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
MA39707A (fr) Dérivés de 1,2-dihydro-3h-pyrrolo [1,2-c]imidazol-3-one et leur utilisation comme agents antibactériens
AR076053A1 (es) Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2014172188A3 (en) 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2012, OBSERVADAS AS CONDICOES LEGAIS